88 related articles for article (PubMed ID: 15755585)
1. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients--an extended open trial.
Abulafia-Lapid R; Mayan S; Bentwich Z; Keren-Zur Y; Avbramovitz Y; Cohen IR; Atlan H
Vaccine; 2005 Mar; 23(17-18):2149-53. PubMed ID: 15755585
[TBL] [Abstract][Full Text] [Related]
2. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients.
Abulafia-Lapid R; Bentwich Z; Keren-Zur Y; Cohen IR; Atlan H
J Clin Virol; 2004 Dec; 31 Suppl 1():S48-54. PubMed ID: 15567094
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
[TBL] [Abstract][Full Text] [Related]
4. Major CD4 epitopes involved in anti-CD4 T-cell autoimmunity in HIV-1 patients.
Abulafia-Lapid R; Keren-Zur Y; Yachnin Y; Atlan H
Vaccine; 2007 Apr; 25(16):3192-9. PubMed ID: 17298856
[TBL] [Abstract][Full Text] [Related]
5. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
6. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects.
Veiga AP; Casseb J; Duarte AJ
Vaccine; 2006 Nov; 24(49-50):7124-8. PubMed ID: 16884833
[TBL] [Abstract][Full Text] [Related]
7. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
Bocket L; Cheret A; Deuffic-Burban S; Choisy P; Gerard Y; de la Tribonnière X; Viget N; Ajana F; Goffard A; Barin F; Mouton Y; Yazdanpanah Y
Antivir Ther; 2005; 10(2):247-54. PubMed ID: 15865219
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.
Tanzi E; Esposito S; Bojanin J; Amendola A; Trabattoni D; Pariani E; Pinzani R; Zanetti A; Principi N
J Med Virol; 2006 Apr; 78(4):440-5. PubMed ID: 16482542
[TBL] [Abstract][Full Text] [Related]
9. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
[TBL] [Abstract][Full Text] [Related]
10. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
[TBL] [Abstract][Full Text] [Related]
11. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.
Lim A; Tan D; Price P; Kamarulzaman A; Tan HY; James I; French MA
AIDS; 2007 Jul; 21(12):1525-34. PubMed ID: 17630546
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
Stone SF; Price P; French MA
HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
Marchetti G; Gori A; Casabianca A; Magnani M; Franzetti F; Clerici M; Perno CF; Monforte Ad; Galli M; Meroni L
AIDS; 2006 Aug; 20(13):1727-36. PubMed ID: 16931937
[TBL] [Abstract][Full Text] [Related]
14. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
15. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
[TBL] [Abstract][Full Text] [Related]
16. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
17. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
19. T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART.
Marziali M; De Santis W; Carello R; Leti W; Esposito A; Isgrò A; Fimiani C; Sirianni MC; Mezzaroma I; Aiuti F
AIDS; 2006 Oct; 20(16):2033-41. PubMed ID: 17053349
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Miro JM; Lopez JC; Podzamczer D; Peña JM; Alberdi JC; Martínez E; Domingo P; Cosin J; Claramonte X; Arribas JR; Santín M; Ribera E;
Clin Infect Dis; 2006 Jul; 43(1):79-89. PubMed ID: 16758422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
